Only 10% of new molecular entities that are in early clinical trials ever make it to approval. However, those with support from genetic evidence are more twice as likely to be approved than those that don’t.
Can you afford not to optimise the use of genomics and genetics in your drug discovery pipeline?
Join us for our latest series: Genomics in Drug Discovery ONLINE, where examples of how to make the best use of genomics and big data will be presented, and how you can utilise these to support your own research.
By the end of the series you will:
- Have an overview of the role that omics play in every stage of drug discovery, and how to manage and integrate diverse data sets.
- Understand how Biobank-scale datasets can be used to validate novel targets.
- Have insights into how, when and where artificial intelligence and machine learning are being utilised to expedite discoveries.
The series outline is below. Plus, each webinar will be presented live, so come armed with questions for the extended Q&A sessions!
**Please note, by registering for one webinar in the series you will automatically gain access to all subsequent webinars in the series**
Thursday 2nd of November at 3pm GMT / 4pm CET / 11am EDT **USA attendees please note that Daylight Saving Time ends on November 5th**
This webinar will discuss how genomics is transforming the drug discovery landscape, revolutionising personalised medicine and identifying the right targets to improve patient outcomes. It will discuss how to manage and analyse the vast amounts of genomic data being generated in research and the clinic, and what tools can be used to support the process.
- Talk 1: From Target Discovery to Clinical Drug Development with Human Genetics
- Katerina Trajanoska, Postdoctoral Research Fellow, McGill University
- Talk 2: Leveraging Public Genomic Data to Identify Therapeutic Targets
- Stefanie Morgan, Head of Science, Watershed Bio
- Talk 3: Discovery Forum: National Genomic Data Driving Pharmaceutical and Biotech R&D
- James Duboff, Strategic Partnerships Director, Genomics England
Thursday 9th November at 3pm GMT / 4pm CET / 10am EST
Introducing the power of multi-dimensional data in drug discovery, this webinar will showcase the value of integrating diverse datasets to lead to more informed pharmaceutical decision-making and accelerated drug development. It will also cover exciting computational tools to directly interpret the results and provide multi-dimensional drug discovery insights.
- Talk 1: Integrating Omics into Drug Discovery: from Target ID to Phase 3 and Beyond
- Tom Lanz, Senior Director of Multi-Omics and Biomarkers, Pfizer
- Talk 2: Advancing Drug Discovery Through Genetics and Genomics
- Nikolina Nakic, Senior Director, Head of V2G2F Computational Biology, GSK
- Talk 3: Multi-Omics Approaches to Inform Disease Mechanism and Drug Target Identification
- Andrew Jarnuczak, Associate Principal Scientist, AstraZeneca
Thursday 16th November at 3pm GMT / 4pm CET / 10am EST
This webinar will discuss how to expertly handle the large sample size data that is required for statistically meaningful target identification, validation and biomarker discovery. It will showcase how the advanced computational prowess of AI can be leveraged for big data, and what to consider when implementing algorithms for this purpose.
- Talk 1: What To Do and What Not To Do? That is the Question
- Gurpreet Singh, Senior Director and Head of Applied Machine Learning, Bayer
- Talk 2: Building AI Models: Lessons Learned
- Richard Lewis, Director, Data Science, Computer-Aided Drug Design, Novartis
- Talk 3: Proteomics and Single-Cell: Applications to the Drug Discovery Process
- Yann Abraham, Associate Scientific Director, Janssen
Postdoctoral Research Fellow at McGill University Canada Excellence Research Chair (CERC) Program in Genomic Medicine